Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 3/20 | 0.56 |
| ▸ | AR | P10275 | 6/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | IL1RN | P18510 | 1/20 | 0.44 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27767404 | 0.78 | MAOA (0.43) | PGRARSMN1; SMN2KMT2ACA1 | |
| SCHEMBL5346498 | 0.78 | CA1 (0.52) | PGRARHPGDKMT2AKEAP1 | |
| SCHEMBL14123868 | 0.78 | RAB9A (0.48) | PGRARHPGDNPC1RAB9A | |
| SCHEMBL4905930 | 0.76 | AR (0.44) | PGRARHPGDKMT2AMAPT | |
| SCHEMBL6007495 | 0.76 | CA1 (0.48) | PGRARHPGDKMT2AKEAP1 | |
| SCHEMBL6007503 | 0.76 | KEAP1 (0.44) | PGRARHPGDKMT2AKEAP1 | |
| SCHEMBL15672897 | 0.74 | CA2 (0.56) | PGRARHPGDSMN1; SMN2KMT2A | |
| SCHEMBL1674268 | 0.74 | KCNA3 (0.50) | KMT2ACA1CA2PKMRECQL | |
| SCHEMBL6533144 | 0.74 | CA1 (0.56) | PGRARHPGDKMT2AKEAP1 | |
| SCHEMBL633995 | 0.74 | KMT2A (0.76) | PGRARHPGDKMT2ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011524358-A | — | — | 2011-09-01 | — | — | JP | claimed |
| EP-2320893-A1 | COMBINATION OF A TRIPTAN AND AN NSAID | Elan Pharma International Limited (IE) | 2011-05-18 | — | — | EP | claimed |
| US-20090311335-A1 | COMBINATION OF A TRIPTAN AND AN NSAID | ALKERMES, INC. | 2009-12-17 | — | — | US | claimed |
| WO-2009152192-A1 | COMBINATION OF A TRIPTAN AND AN NSAID | ELAN PHARMA INTERNATIONAL LIMITED (IE) | 2009-12-17 | — | — | WO | claimed |
| EP-1617816-B1 | NANOPARTICULATE MELOXICAN FORMULATIONS | ELAN PHARMA INT LTD (IE) | 2009-05-13 | — | — | EP | claimed |
| EP-1938803-A2 | Formulations comprising nanoparticulate meloxican | Elan Pharma International Limited (IE) | 2008-07-02 | — | — | EP | claimed |
| EP-1617816-A2 | NANOPARTICULATE MELOXICAN FORMULATIONS | Elan Pharma International Limited (IE) | 2006-01-25 | — | — | EP | claimed |
| WO-2005002542-A2 | NANOPARTICULATE MELOXICAN FORMULATIONS | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2005-01-13 | — | — | WO | claimed |
| US-20040229038-A1 | Nanoparticulate meloxicam formulations | ELAN PHARMA INTERNATIONAL LTD. | 2004-11-18 | — | — | US | claimed |
| US-20210113580-A1 | NANOPARTICULATE MELOXICAM FORMULATIONS | BAUDAX BIO, INC. | 2021-04-22 | — | — | US | disclosed |
| EP-3434261-B1 | FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM | BAUDAX BIO INC (US) | 2020-10-28 | — | — | EP | disclosed |
| US-10709713-B2 | Nanoparticulate meloxicam formulations | BAUDAX BIO, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20200155564-A1 | Nanoparticulate Meloxicam Formulations | RECRO TECHNOLOGY LLC | 2020-05-21 | — | — | US | disclosed |
| US-10471067-B2 | Nanoparticulate meloxicam formulations | RECRO PHARMA, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| EP-1651189-A1 | NOVEL METAXALONE COMPOSITIONS | Elan Pharma International Limited (IE) | 2006-05-03 | — | — | EP | disclosed |
| EP-1617816-A2 | NANOPARTICULATE MELOXICAN FORMULATIONS | Elan Pharma International Limited (IE) | 2006-01-25 | — | — | EP | disclosed |
| US-20050063913-A1 | Novel metaxalone compositions | ELAN PHARMA INTERNATIONAL, LTD. | 2005-03-24 | — | — | US | disclosed |
| WO-2005016310-A1 | NOVEL METAXALONE COMPOSITIONS | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2005-02-24 | — | — | WO | disclosed |
| WO-2005002542-A2 | NANOPARTICULATE MELOXICAN FORMULATIONS | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2005-01-13 | — | — | WO | disclosed |
| US-20040229038-A1 | Nanoparticulate meloxicam formulations | ELAN PHARMA INTERNATIONAL LTD. | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050063913-A1 | Novel metaxalone compositions | MTX1, MTX2, TBXA2R | PGR 1583/4885AR 1575/4885HPGD 358/4885 |
| US-20200155564-A1 | Nanoparticulate Meloxicam Formulations | MTNR1A, MB, MTDH | PGR 2695/4885AR 3770/4885HPGD 347/4885 |
| US-10709713-B2 | Nanoparticulate meloxicam formulations | MTNR1A, MB, MTDH | PGR 2695/4885AR 3770/4885HPGD 347/4885 |
| US-10471067-B2 | Nanoparticulate meloxicam formulations | MTNR1A, MB, MTDH | PGR 2695/4885AR 3770/4885HPGD 347/4885 |
| US-20210113580-A1 | NANOPARTICULATE MELOXICAM FORMULATIONS | MTNR1A, MB, MTDH | PGR 2695/4885AR 3770/4885HPGD 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.